Oppenheimer Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Oppenheimer Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.49M	Buy	14,783 +470	+3%	+$69.7K	0.03%	533
2026 Q1	$1.89M	Sell	14,313 -99	-0.7%	-$13.1K	0.02%	569
2025 Q4	$2.04M	Sell	14,412 -968	-6%	-$140K	0.03%	497
2025 Q3	$2.16M	Sell	15,380 -815	-5%	-$110K	0.02%	541
2025 Q2	$2.04M	Buy	16,195 +2,202	+16%	+$253K	0.02%	547
2025 Q1	$1.55M	Buy	13,993 +49	+0.4%	+$6.21K	0.02%	599
2024 Q4	$1.9M	Buy	13,944 +186	+1%	+$23K	0.02%	549
2024 Q3	$1.59M	Sell	13,758 -1,388	-9%	-$190K	0.02%	614
2024 Q2	$2.09M	Buy	15,146 +1,725	+13%	+$237K	0.03%	511
2024 Q1	$1.85M	Sell	13,421 -2,056	-13%	-$281K	0.03%	512
2023 Q4	$2.04M	Sell	15,477 -452	-3%	-$52K	0.03%	510
2023 Q3	$1.79M	Buy	15,929 +1,736	+12%	+$183K	0.03%	527
2023 Q2	$1.34M	Sell	14,193 -12,027	-46%	-$1.18M	0.02%	612
2023 Q1	$2.65M	Sell	26,220 -196	-0.7%	-$20.4K	0.04%	418
2022 Q4	$3.16M	Sell	26,416 -3,833	-13%	-$449K	0.05%	365
2022 Q3	$3.21M	Sell	30,249 -3,444	-10%	-$349K	0.06%	338
2022 Q2	$3.29M	Sell	33,693 -920	-3%	-$84.9K	0.06%	347
2022 Q1	$3.25M	Buy	34,613 +8,179	+31%	+$693K	0.05%	399
2021 Q4	$2.25M	Sell	26,434 -2,362	-8%	-$217K	0.03%	520
2021 Q3	$2.76M	Buy	28,796 +354	+1%	+$33.4K	0.04%	428
2021 Q2	$2.77M	Buy	28,442 +674	+2%	+$64.6K	0.04%	442
2021 Q1	$2.7M	Buy	27,768 +2,532	+10%	+$266K	0.04%	427
2020 Q4	$2.42M	Sell	25,236 -639	-2%	-$61.7K	0.04%	423
2020 Q3	$2.49M	Buy	25,875 +16,149	+166%	+$1.87M	0.05%	381
2020 Q2	$1.19M	Buy	9,726 +785	+9%	+$86.7K	0.02%	547
2020 Q1	$774K	Buy	8,941 +1,383	+18%	+$135K	0.02%	621
2019 Q4	$812K	Buy	7,558 +82	+1%	+$8.59K	0.02%	683
2019 Q3	$674K	Buy	7,476 +204	+3%	+$19.1K	0.02%	729
2019 Q2	$614K	Sell	7,272 -203	-3%	-$16.7K	0.01%	763
2019 Q1	$659K	Buy	7,475 +700	+10%	+$58.5K	0.01%	719
2018 Q4	$484K	Buy	+6,775	New	+$649K	0.01%	777

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Oppenheimer Asset Management's NBIX Position: Q2 2026 in Review

Oppenheimer Asset Management increased its Neurocrine Biosciences (NBIX) stake by 3.3% in Q2 2026, buying an estimated $69.7K and bringing the position to 14,783 shares worth $2.49M. The position accounts for 0.03% of the portfolio, ranked #533.

Oppenheimer Asset Management first reported a position in NBIX in Q4 2018 and has held it in 31 quarters since. The position peaked at $3.29M in Q2 2022. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Oppenheimer Asset Management held 14,783 shares of Neurocrine Biosciences worth $2.49M as of Q2 2026.
Oppenheimer Asset Management bought 470 Neurocrine Biosciences shares in Q2 2026, an estimated $69.7K.
Neurocrine Biosciences made up 0.03% of Oppenheimer Asset Management's portfolio in Q2 2026, its #533 holding.
Oppenheimer Asset Management first reported a position in Neurocrine Biosciences in Q4 2018 and has held it in 31 quarters since.
Oppenheimer Asset Management's Neurocrine Biosciences position peaked at $3.29M in Q2 2022.
781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.